Dasher Neuroscience Holdings Inc
TTPEX:782952.90
TWD
+1.70
(+3.32%)
ISIN
KYG8851R1065
CUSIP
G8851R106
Return %
Stock
S&P 500
1Y
-12.75
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Semi-annual Revenue
TWD
•
in mil. unless spec.Semi-annual Earnings Per Share
TWD
•
in mil. unless spec.Semi-annual Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Yu Feng Tseng
- Full Time Employees
- 19
- Sector
- Technology services
- Industry
- Packaged software
- Address
- Taipei Taiwan
- Similar Companies
- Business
- Dasher Neuroscience Holdings Inc. (TPEx: 7829), formerly known as Yoda Pharmaceuticals Inc., is a clinical-stage biopharmaceutical company that specializes in artificial intelligence-driven drug discovery and development for central nervous system (CNS) and neurodegenerative disorders. Founded in 2019 and headquartered in Taipei, Taiwan, with corporate registration in the Cayman Islands, the company originated from academic and clinical research collaborations across National Taiwan University, National Yang Ming Chiao Tung University, and the National Health Research Institutes, and was incubated through Taiwan national research initiatives alongside Stanford University's SPARK program. Dasher Neuroscience operates within the biotechnology and pharmaceutical research industry, targeting unmet medical needs for patients afflicted with rare, neurodegenerative, psychiatric, and cerebrovascular conditions across global markets, including North America, Europe, and the Asia-Pacific region. The company's core product portfolio and research capabilities center on proprietary small molecule therapeutics developed through its integrated AI drug screening platform: YA-101, a flagship small molecule candidate in global Phase 2 clinical development for the treatment of Multiple System Atrophy (MSA), which has secured Orphan Drug Designation from the U.S. Food and Drug Administration, the European Medicines Agency, and Japan's Ministry of Health, Labour and Welfare, along with U.S. FDA Fast Track Designation; YA-102, an investigational therapeutic program targeting Parkinson's disease; YA-201, a preclinical drug candidate directed toward Alzheimer's disease pathology; YA-301, a research-stage compound focused on the treatment of schizophrenia; YA-501, an early-stage asset targeting cerebrovascular conditions; and proprietary AI computational drug discovery and screening services utilized to accelerate target identification, lead optimization, and translational preclinical validation for complex neurological targets. In recent corporate developments, the company executed a strategic corporate reorganization and rebranding in 2026, renaming its core operating subsidiary from Yoda Therapeutics Inc. to Dasher Neuroscience Inc. and unifying its holding operations under the Dasher Neuroscience identity on the Taiwan Emerging Stock Board (TPEx: 7829). In July 2026, the company achieved a critical operational milestone by completing patient enrollment for its global, multi-center Phase 2 clinical trial of lead asset YA-101 in Multiple System Atrophy, with top-line data readouts scheduled for the first quarter of 2027. Additionally, the organization has expanded its international clinical trial network and academic partnerships, including research collaborations with European centers to participate in multi-arm clinical platform initiatives such as Norway's HYDRA study for Parkinson's disease.